email article
The oral JAK inhibitor upadacitinib (Rinvoq), approved for use in rheumatoid arthritis, also showed promise for psoriatic arthritis in a phase III trial comparing the drug with placebo and adalimumab (Humira).
At week 12, 20% improvements on the criteria of the American College of Rheumatology (ACR20) were seen in 70.6% of patients receiving 15 mg daily of upadacitinib; 78.5% of those given 30 mg per day; 65% of those receiving subcutaneous adalimumab, 40 mg every other week; and 36.2% of those assigned to placebo, reported Iain B. McInnes, MD, PhD, of the University of Glasgow in Scotland, and colleagues.
Both upadacitinib doses were noninferior to adalimumab on the ACR20 criteria, and the 30 mg dose was superior, the investigators reported in the study online in the
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
like 5g. almost all the fortune 500 partner with us. (woman) when it comes to digital transformation. verizon keeps business ready. if you have moderate to severe plaque psoriasis, every day can begin with flakes. it s a reminder of your struggles with psoriasis. but what if your psoriasis symptoms didn t follow you around? that s why there s ilumya.
but what if your psoriasis symptoms didn t follow you around? that s why there s ilumya. with just 2 doses, a majority of people were clear or almost clear. and over time, even more people were clear or almost clear. all with dosing 4 times a year. after 2 initial doses. plus, ilumya was shown to have similar risks of infections compared to placebo. don t use if you are allergic to ilumya or any of its ingredients. before starting treatment, your doctor should check for tuberculosis and infections. after checking there is no need for routine lab monitoring unless your doctor advises it. ilumya may increase your risk of infections and lower your ability to fight them. tell your doctor if you have an infection or have symptoms, or if you plan to or have recently received a vaccine. this could be your chance to leave your psoriasis symptoms behind. ask your doctor for ilumya today, for a clearer tomorrow.